Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP

Pancreatic cancer is chemo-resistant and metastasizes early with an overall five-year survival of ∼8.2%. First-in-class imipridone ONC201 is a small molecule in clinical trials with anti-cancer activity. ONC212, a fluorinated-ONC201 analogue, shows preclinical efficacy in melanoma and hepatocellular...

全面介紹

Na minha lista:
書目詳細資料
發表在:Oncotarget
Main Authors: Lev, Avital, Lulla, Amriti R., Wagner, Jessica, Ralff, Marie D., Kiehl, Joshua B., Zhou, Yan, Benes, Cyril H., Prabhu, Varun V., Oster, Wolfgang, Astsaturov, Igor, Dicker, David T., El-Deiry, Wafik S.
格式: Artigo
語言:Inglês
出版: Impact Journals LLC 2017
主題:
Priority Research Paper
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5669847/
https://ncbi.nlm.nih.gov/pubmed/29137221
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20819
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍